Tag Archives: Spectra optia

Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients

LAKEWOOD, CO. USA – 10 April 2020 – Terumo BCT, Inc. and Marker Therapeutics AG announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the use of Terumo BCT’s Spectra Optia® Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed […]